ESPE Abstracts

Background: Achondroplasia is the most common condition characterized by disproportionate short stature. Patients with achondroplasia progressively fall below normal standards for length and height. GH has been widely used to treat short stature with or without GH deficiency (GHD).Objective and hypotheses: The purpose of the present study was to clarify the effectiveness of GH therapy on short stature in achondroplasia.Method: The ...

Background: The incidence of type 1 diabetes mellitus (T1DM) in children and adolescents has increased worldwide. However, the epidemiology of T1DM among Korean children has not been reported since 2001.Objective and hypotheses: We therefore investigated the incidence of T1DM in Korean children and adolescents in 2012–2013 and compared it with data from 1995–2000.Method: Data were obtained from the National Health Insuran...

Background: There have been reports that patients with diabetes have hearing loss greater than those without. Suggested pathogenesis for diabetes-associated hearing loss has included cochlear microangiopathy, hyperglycaemia of cerebrospinal fluid, auditory neuropathy and diabetic encephalopathy.Objective and hypotheses: This study is aimed to investigate hearing changes in children and adolescents with type 1 diabetes mellitus and to examine if hearing c...

Background: Serum FGF-21 levels are increased in adults with obesity, type 2 diabetes and nonalcoholic fatty liver disease (NAFLD). Serum FGF-21 levels have been implicated as a potential biomarker for early detection of the metabolic syndrome (MetS) and type 2 diabetes in adults. However, there are only a few studies about the correlation between FGF-21 levels and metabolic parameters in children.Aims and objective: This study is aimed to evaluate the r...

Background: Idiopathic short stature (ISS) is defined as short stature of unknown origin. It is apparently not associated with GH deficiency (GHD). High-dose GH treatment is considered to be more beneficial in children with ISS than in those with GHD. However, responses to GH in children with ISS are highly variable and dose-dependent, and the optimal treatment is controversial.Aims: To compare the effects of low-dose GH treatment in children with GHD vs...

Background: Precocious puberty is one of the fastest-growing paediatric diseases in South Korea. As the UCC (User Created Contents) has provided lots of medical information, it becomes an easy and important source of medical information.Objective and hypotheses: This study aimed to investigate and to evaluate the quality and scientific accuracy of precocious puberty-related UCC on Youtube.Method: The key words ‘precocious pube...

The proband is a 12 yr old Caucasian European girl with grade 3 obesity, developmental delay and hyperphagia. She was born at term via an uncomplicated pregnancy and exhibited neonatal hypotonia, difficulty feeding, failure to thrive and delayed attenuation of milestones. At the age of 2 years she started developing hyperphagia and rapid excessive weight gain. Molecular analysis for Prader Willi syndrome and array CGH were negative. At the age of 10 yrs she was diagnosed with ...

Objectives: Convenience of growth hormone (GH) use can lead to good adherence and result in satisfactory treatment outcomes. The aim of this study is to compare the long-term efficacy of weekly GH with daily GH in children with GH deficiency (GHD).Methods: Clinical data of 966 GHD children (773 treated with daily GH and 193 treated with weekly GH) were obtained from the “LG Growth Study”, which is an observat...

Background: The diagnosis of growth hormone deficiency (GHD) requires the subnormal responses to two provocation tests. This study evaluated the value of the growth hormone provocation test using arginine and insulin-induced hypoglycemia to diagnose growth hormone deficiency (GHD).Method: This study included 294 children with short stature (136 girls and 158 boys) who underwent a growth hormone provocation test using the...

Objectives: Somatrogon is a long-acting recombinant human growth hormone (GH) approved in the EU and other countries for once-weekly treatment of pediatric patients with GH deficiency (GHD). In this analysis, height outcomes of somatrogon-treated patients in a phase 3 trial (CP-4-006) were compared with historical data from matched somatropin-treated patients enrolled in KIGS.Methods: In trial CP-4-006, patients were ran...